pentobarbital will lessen the level or effect of paclitaxel by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Mysterious.
pentobarbital will minimize the extent or result of finasteride by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unknown.
pentobarbital will decrease the extent or impact of diltiazem by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep track of.
pentobarbital will lower the extent or outcome of amlodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on.
pentobarbital will lower the extent or outcome of isavuconazonium sulfate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.
Premature infants are notably liable to the depressant effects of barbiturates; if barbiturates are employed through labor and delivery, resuscitation gear must be readily available
pentobarbital will reduce the extent or effect of cobimetinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Stay clear of coadministration. Strong or moderate CYP3A inducers may well decrease cobimetinib systemic publicity by >eighty% and decrease its efficacy.
pentobarbital will reduce the extent or effect of aprepitant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Check.
pentobarbital will lower the level or impact of artemether/lumefantrine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Stay away from or Use Alternate Drug. Coadministration with sturdy CYP3A4 inducers may lead to diminished serum concentrations and loss of antimalarial efficacy
pentobarbital will lower the extent or influence of atazanavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Mysterious.
Subsequent oral or parenteral administration, barbiturates easily cross the placental barrier and they are distributed during fetal tissues with greatest concentrations located in the placenta, fetal liver, and Mind; fetal blood amounts strategy maternal blood levels pursuing parenteral administration
pentobarbital will lessen the extent or effect of piroxicam by impacting hepatic enzyme CYP2C9/ten metabolism. Insignificant/Significance Unidentified.
pentobarbital will decrease the extent or outcome of roflumilast by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not encouraged; solid cytochrome P450 enzyme inducers lessen systemic exposure to roflumilast and may reduce the therapeutic success
Phenytoin and barbiturate blood levels need to be monitored additional usually if given concurrently; influence of barbiturates on phenytoin metabolism claimed for being variable; sodium valproate and valproic acid surface to more info lower barbiturate metabolism; monitor barbiturate blood degrees and make appropriate dosage adjustments as important